Format

Send to:

Choose Destination
See comment in PubMed Commons below
Mol Cancer Res. 2014 Nov;12(11):1535-46. doi: 10.1158/1541-7786.MCR-13-0641. Epub 2014 Aug 6.

MicroRNA-26a/b Regulate DNA Replication Licensing, Tumorigenesis, and Prognosis by Targeting CDC6 in Lung Cancer.

Author information

  • 1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China.
  • 2Guangzhou HKUST Fok Ying Tung Research Institute, Guangzhou, China. Division of Life Science and Center for Cancer Research, Hong Kong University of Science and Technology, Hong Kong, China.
  • 3Guangzhou HKUST Fok Ying Tung Research Institute, Guangzhou, China. Division of Life Science and Center for Cancer Research, Hong Kong University of Science and Technology, Hong Kong, China. bccliang@ust.hk hejx@vip.163.com.
  • 4Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China. bccliang@ust.hk hejx@vip.163.com.

Abstract

Cancer is characterized by mutations, genome rearrangements, epigenetic changes, and altered gene expression that enhance cell proliferation, invasion, and metastasis. To accommodate deregulated cellular proliferation, many DNA replication-initiation proteins are overexpressed in human cancers. However, the mechanism that represses the expression of these proteins in normal cells and the cellular changes that result in their overexpression are largely unknown. One possible mechanism is through miRNA expression differences. Here, it is demonstrated that miR26a and miR26b inhibit replication licensing and the proliferation, migration, and invasion of lung cancer cells by targeting CDC6. Importantly, miR26a/b expression is significantly decreased in human lung cancer tissue specimens compared with the paired adjacent normal tissues, and miR26a/b downregulation and the consequential upregulation of CDC6 are associated with poorer prognosis of patients with lung cancer. These results indicate that miR26a/b repress replication licensing and tumorigenesis by targeting CDC6.

IMPLICATIONS:

The current study suggests that miR26a, miR26b, and CDC6 and factors regulating their expression represent potential cancer diagnostic and prognostic markers as well as anticancer targets. Mol Cancer Res; 12(11); 1535-46. ©2014 AACR.

©2014 American Association for Cancer Research.

PMID:
25100863
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk